PODCAST: Maha Hussain about the IMvigor010 study

July 2020 ASCO 2020 Marjolein Groot

In this podcast, prof. dr. Maha Hussain explains the results of the primary analysis of the fase III IMvigor010 study. In this trial, patients with high-risk muscle-invasive urothelial carcinoma were, after surgical resection, randomized to atezolizumab, an anti-PD-L1 antibody, or observed. Listen now to hear prof. dr. Hussain elaborate on the results and implications of this study.